関連する実験動画
Updated: May 5, 2026

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.5K
インターフェロン-β治療は,心臓型ウイルスを排除し,ウイルスゲノムの心筋持続性および左心室機能不全を有する患者の左心室機能を改善します
Uwe Kühl1, Matthias Pauschinger, Peter Lothar Schwimmbeck
1Department of Cardiology and Pneumology, University Hospital Benjamin-Franklin, Freie Universität Berlin, Germany. dcmkuehl@zedat.fu-berlin.de
Circulation
|May 29, 2003
まとめ
インターフェロン (IFN) -β治療は,持続性心筋炎の患者のウイルス感染症を成功裏に除去しました. この治療法により,左心室の機能と直径が改善され,安全性と有効性が実証されました.
科学分野:
- 心臓病学 心臓病学
- ウイルス学 ウイルス学 ウイルス学
- 免疫学 免疫学とは
背景:
- ウイルス感染症は心筋梗塞の重要な原因であり,潜在的に拡張性心筋症および心臓機能不全につながる可能性があります.
- 心筋膜ウイルス持続は,慢性的な左心室 (LV) 機能不全を引き起こす可能性があります.
研究 の 目的:
- 持続性ウイルス性心筋炎の患者におけるインターフェロン (IFN) -β治療の安全性と有効性を評価する.
- IFN-β治療でウイルスのクリアランスを達成し,LV機能の悪化を防ぐことができるかどうかを判断する.
主な方法:
- ポリメラーゼ連鎖反応で証明されたエンテロウイルスまたはアデノウイルスゲノムと持続的なLV機能障害を持つ22人の患者を含む第2相研究.
- 患者は24週間にわたって皮下IFN-β (18x10^6 IU/週) を投与された.
- 心筋炎症は,心筋内部の生検で評価され,心筋内部の機能は,心声検査と血管検査で評価された.
主要な成果:
- IFN-βはよく耐受され,治療中に悪化した患者はいなかった.
- ウイルスゲノムの完全なクリアランスは22人の患者全員で観察されました.
- LV機能の有意な改善が認められた: LV直径の減少 (終間ダイアストリックと終間シストリック) と,LVエジェクション分数の増加 (P<0.001).
結論:
- IFN-βの6ヶ月の治療は,心筋ウイルス持続性およびLV機能不全の患者に安全です.
- この治療は,治療を受けたすべての患者のウイルスゲノムを効果的に排除しました.
- IFN-β治療は,患者の大半 (22 件中 15 件) で LV 機能の改善につながった.
関連する概念動画
Heart Failure Drugs: β-Blockers
2.7K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.7K
Myocarditis III: Medical Management
343
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
343
Cardiomyopathy II: Dilated Cardiomyopathy
790
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy IV: Restrictive Cardiomyopathy
952
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
952
Cardiomyopathy V: Interprofessional Care
753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Inhibitors of Viral Protein Synthesis
58
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58

